title: High pretreatment neutrophil-lymphocyte ratio predicts recurrence and poor prognosis for combined small cell lung cancer.
abstract: BACKGROUND
  Compared to pure small cell lung cancer (SCLC), combined small cell lung cancer (C-SCLC) has its own characteristics. High neutrophil to lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) have been shown to be related to poor prognosis in several types of tumors. The aim of this study was to explore the prognosis value of NLR and PLR in patients with C-SCLC.
  
  
  METHODS
  A total of 112 patients diagnosed with C-SCLC between January 2000 and March 2009 were enrolled in the study. The clinicopathological parameters, laboratory analyses, and survival time were collected and analyzed. The correlation between NLR, PLR, and clinicopathological characters was analyzed. Univariate and multivariate analyses were performed to investigate the prognostic significance of these parameters for C-SCLC.
  
  
  RESULTS
  The pretreatment NLR was elevated in 37.5 % patients (NLR ≥ 4.15; n = 42; H-NLR). NLR was significantly related to disease stage (p = 0.033) and tumor recurrence (p = 0.014). The median overall survival (OS) and progression-free survival (PFS) were significantly worse in the H-NLR group (OS: 22.0 months vs 11.7 months, p = 0.001; PFS: 11.1 vs 6.0 months, p < 0.001). However, PLR at diagnosis was not associated with OS or PFS. Multivariate analyses indicated elevated NLR (HR = 1.6; p = 0.001), disease stage (HR = 1.6; p = 0.001), and performance status (HR = 1.8; p = 0.015) as independent prognostic factors.
  
  
  CONCLUSIONS
  High pretreatment NLR (≥4.15) is a potential useful indicator for C-SCLC recurrence and predicts a poor long-term prognosis for C-SCLC, which should be considered in defining the prognosis with other well-known prognosticators in C-SCLC patients.
authors.affiliation: Department of Respiratory Medicine, Tianjin Hospital of ITCWM, Nankai Hospital, Changjiang Road, Nankai District, Tianjin, 300100, China. dr_shaona@163.com.
authors.forename: N
authors.initials: N
authors.lastname: Shao
authors.affiliation: Department of Respiratory Medicine, Tianjin Hospital of ITCWM, Nankai Hospital, Changjiang Road, Nankai District, Tianjin, 300100, China.
authors.forename: Q
authors.initials: Q
authors.lastname: Cai
mesh_terms: D000230:Adenocarcinoma / Q000097:blood* / Q000473:pathology / Q000628:therapy; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001792:Blood Platelets; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D018287:Carcinoma, Large Cell / Q000097:blood* / Q000473:pathology / Q000628:therapy; D002294:Carcinoma, Squamous Cell / Q000097:blood* / Q000473:pathology / Q000628:therapy; D015331:Cohort Studies; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D000077146:Irinotecan; D007958:Leukocyte Count; D008175:Lung Neoplasms / Q000097:blood* / Q000473:pathology / Q000628:therapy; D018655:Lymphocyte Count; D008214:Lymphocytes; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000097:blood* / Q000473:pathology / Q000628:therapy; D009367:Neoplasm Staging; D018193:Neoplasms, Complex and Mixed / Q000097:blood* / Q000473:pathology / Q000628:therapy; D009504:Neutrophils; D010976:Platelet Count; D017671:Platinum Compounds / Q000008:administration & dosage; D011013:Pneumonectomy; D011379:Prognosis; D011878:Radiotherapy; D012189:Retrospective Studies; D055752:Small Cell Lung Carcinoma / Q000097:blood* / Q000473:pathology / Q000628:therapy
chemical_list: D017671:Platinum Compounds; D000077146:Irinotecan; D002166:Camptothecin
keywords: Combined small cell lung cancer; Neutrophil to lymphocyte ratio; Prognosis; Tumor-related inflammation